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Objectives. The purpose of this study was to evaluate whether a
serotonin blocker, sarpogrelate, improves exercise capacity as a
result of vasodilation of coronary collateral channels in patients
with effort angina.
Background. Serotonin has been reported to decrease coronary
collateral blood flow by collateral vasoconstriction in a canine
model, suggesting that platelet activation in feeding coronary
arteries of the collateral network has the potential to cause
collateral vasoconstriction.
Methods. The subjects consisted of 22 patients with effort
angina and reproducible ischemic threshold (group A, 11 patients
with thrombolysis in myocardial infarction (TIMI) grade 2 or 3
flow of the ischemia-related coronary artery and Rentrop’s collat-
eral index 0 or 1; group B, 11 patients with TIMI grade 0 or 1 flow
and Rentrop’s collateral index 2 or 3). We repeated the symptom-
limited treadmill exercise test using the Balke–Ware protocol and
exercise tetrofosmin myocardial perfusion scintigraphy with and
without pretreatment with 200 mg orally administered sarpogre-
late. Each exercise test was performed at 9:00 a.m. on different
days. The order of tests with and without sarpogrelate was
randomized.
Results. In group A, sarpogrelate increased neither exercise
time at 0.1 mV ST depression nor double product at 0.1 mV ST
depression. In contrast, in group B sarpogrelate increased the
exercise duration at 0.1 mV ST depression from 181 6 112 (SD) to
248 6 131 s (p < 0.05) and also increased the double product at
0.1 mV ST depression by 21% (p < 0.01). The severity score using
myocardial perfusion scintigraphy at the same workload was
significantly (p < 0.01) decreased by 37% in group B, but not in
group A (11%), due to the sarpogrelate treatment.
Conclusions. Sarpogrelate augments flow reserve of the collat-
eral circulation and improves exercise capacity in anginal patients
with well-developed collaterals. These findings indicate that a
serotonin blocker, sarpogrelate, is useful not only as an antiplate-
let drugs, but as an antianginal drug.
(J Am Coll Cardiol 1998;32:1982–6)
©1998 by the American College of Cardiology
Although well-developed collateral vessels can provide protec-
tion against ischemia and infarction in patients with coronary
artery disease, vasodilator reserve in the collateral dependent
region is limited. Since fully developed collateral vessels have
a well-developed muscular layer, their tone can be affected by
various vasoactive substances. Indeed, we have previously
demonstrated that collateral vasodilation accompanying ni-
trate administration greatly contributes to the improvement in
exercise capacity (1).
Serotonin, as a product of aggregating platelets, is reported
to reduce blood flow through well-developed collaterals in a
canine model (2). It is assumed that platelet activation in the
donor coronary arteries involved in collateral circulation has
the potential to decrease blood flow to the collateral depen-
dent jeopardized myocardium by causing collateral vasocon-
striction. Accordingly, we hypothesized that a serotonin
blocker, sarpogrelate, would improve exercise capacity as a
result of vasodilation of coronary collateral vessels.
Thus, the present study was designed to evaluate whether
sarpogrelate administration increases blood flow to the collat-
eral dependent area, perfused by the totally occluded coronary
artery, in patients with stable effort angina.
Methods
Patients. We studied 22 patients (17 men and 5 women)
between 46 and 83 years of age (mean, 66 6 10 years) with
stable effort angina. All had angiographically proven significant
coronary stenosis ($70%) involving one or more major coro-
nary arteries and developed $1 mm ST segment depression
during treadmill exercise testing. None had suffered a previous
myocardial infarction or acute exacerbation of symptoms in the
preceding six months. A treadmill exercise and exercise myo-
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cardial scintigraphy were performed after withdrawal of all
antianginal medications for at least 48 h. All subjects gave
written informed consent for this study.
Cardiac catheterization. All patients were referred for
conventional diagnostic right and left heart catheterization,
together with left ventriculography and selective coronary
angiography, to evaluate coronary atherosclerotic lesions and
left ventricular function. All medications were withheld for
$24 h before the procedure. Selective coronary arteriography
was performed using the femoral approach. A contrast me-
dium was injected with enough force and in sufficient quantity
to provide good visualization of the coronary arteries. Multiple
projections of right and left coronary arteries were routinely
obtained. After left ventricular pressure had returned to
baseline levels, left ventricular cineangiography was performed
at a 30° right anterior oblique projection. The diameter of the
coronary arteries was measured with a caliper on suitably
magnified 35 mm cineframes at end-diastole. A significant
coronary stenosis was defined as $70% narrowing of a major
coronary artery branch.
Grading of coronary perfusion. The degree of perfusion of
the ischemia-related coronary artery was graded on a scale of
0 to 3 as follows: 0 5 there is no anterograde flow beyond the
point of occlusion; 1 5 the contrast material passes beyond the
area of obstruction but “hangs up” and fails to opacify the
entire coronary bed distal to the obstruction for the duration of
the cineangiographic filming sequence; 2 5 the contrast ma-
terial passes across the obstruction and opacifies the coronary
bed distal to the obstruction. However, the rate of entry of the
contrast material into the vessel distal to the obstruction, or its
rate of clearance from the distal bed (or both) is perceptibly
slower than its entry into or clearance from comparable areas
(for example, the opposite coronary artery or the coronary bed
proximal to the obstruction); 3 5 anterograde flow into the bed
distal to the obstruction occurs as quickly as anterograde flows
into the bed proximal to the obstruction, and clearance of
contrast material from the involved bed is as rapid as clearance
from an uninvolved bed in the same vessel or the opposite
artery (3).
Grading of coronary collateral filling. Collateral circula-
tion was graded on a scale of 0 to 3 depending on the degree
of opacification of the occluded vessel. The score (collateral
index) was based on the injection that best opacified the
occluded vessel: 0 5 none; 1 5 filling of side branches of the
artery to be perfused with collateral vessels and no visualiza-
tion of the epicardial segment; 2 5 partial filling of the
epicardial segment with collateral vessels; 3 5 complete filling
of the epicardial segment with collateral vessels (4). Three
observers assessed the coronary cineangiograms in blinded
fashion and reached a consensus regarding the Thrombolysis
in Myocardial Infarction (TIMI) grade and collateral filling.
Subgroups. The patients were divided into two groups
according to the degree of perfusion of the ischemia-related
coronary artery: group A (n 5 11), patients with TIMI grade 2
or 3 flow and Rentrop’s collateral index 0 or 1; and group B
(n 5 11), those with TIMI grade 0 or 1 flow and Rentrop’s
collateral index 2 or 3.
Protocol. Two treadmill tests with and without sarpogre-
late pretreatment (200 mg, one hour prior to the test) were
performed at 9 a.m. on different days within a week. To
minimize the effects of habituation to the treadmill test, the
order of tests with and without sarpogrelate was randomized.
Over one week, two exercise 99mTc-tetrofosmin myocardial
perfusion studies were repeated with and without sarpogrelate
pretreatment, with the same workload, at 9 a.m. on different
days. All patients received neither a placebo nor an active drug
before each test.
Treadmill exercise testing. Symptom-limited graded
treadmill exercise testing was performed using the Balke-Ware
protocol (5) with all patients undergoing two exercise tests. A
12-lead ECG was recorded at rest and at 30-second intervals
until the onset of limiting chest pain, leg fatigue or $2 mm ST
segment depression. Blood pressure was measured with a
sphygmomanometer at the end of each stage. In this study, the
heart rate and blood pressure at the onset of 1 mm ST segment
depression were measured to determine the ischemic thresh-
old. Analysis on all tests was performed by two independent
observers who were not aware of the conditions of the exercise
tests.
Tetrofosmin myocardial perfusion scintigraphy. Following
an overnight fast, a tetrofosmin study was performed at rest
and during exercise (6). For the stress tetrofosmin study, a
bicycle ergometer exercise was begun at a workload of 25 watts
and increased in steps of 25 watts every 2 min. Blood pressure
was measured once a minute using a sphygmomanometer. The
electrocardiogram was closely monitored throughout the exer-
cise and recovery. In the initial test, exercise was terminated
when patients experienced severe chest pain or the ST segment
was depressed more than 2 mm. At peak exercise, 370 to
592 MBq (10 to 16 mCi) of 99mTc-tetrofosmin was intrave-
nously injected, and exercise was extended for an additional
minute. After 10 to 15 min of recovery time, each patient was
asked to have a light meal or a glass of milk to accelerate
hepatobiliary clearance. Imaging was done approximately 30 to
40 min after the radiopharmaceutical administration. Tomog-
raphy was obtained with a rotational gamma camera collecting
32 20 s views over 180°. The total acquisition time was
approximately 12 min. The resting tetrofosmin study was
performed 24 to 72 h after the stress imaging. Following
administration of 370 to 592 MBq (10 to 16 mCi) of 99mTc-
tetrofosmin at rest in a fasting state, a light meal or a glass of
milk was given. About 40 min after the tracer administration,
resting tomography was performed in a similar fashion (6).
Myocardial images were divided into 18 segments in the
short axis (apical, midventricular and basal slices) plus two
segments in the vertical long axis for apical perfusion. Three
expert observers assessed tetrofosmin uptake by visual inspec-
tion based on a 0 to 3 score, in which 0 5 normal perfusion,
1 5 mild perfusion defects, 2 5 moderate perfusion defects
and 3 5 severe perfusion defects (7). Disagreements were
resolved by consensus.
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Statistical analysis. Data are expressed as the mean 6 SD.
A two-way ANOVA using Bonferroni’s method was carried
out to investigate differences in the treadmill exercise test.
Student t test was used to compare the severity score in stress
myocardial perfusion scintigraphy. Significance was designated
at the probability value of p , 0.05.
Results
Patient profile. The clinical and angiographic characteris-
tics of all patients are shown in Table 1. The distribution of the
ischemia-related artery was quite similar in each group. The
incidence of multivessel disease was also comparable in the
two groups. The left ventricular ejection fraction was 60 6 5%
in group A, which was greater than the 54 6 10% in group B.
Exercise capacity with and without sarpogrelate treatment.
Exercise time and hemodynamic parameters at rest and at
0.1 mV ST depression during the treadmill exercise test, with
and without sarpogrelate pretreatment, are summarized in
Table 2. In group A, the exercise time remained unchanged
despite sarpogrelate pretreatment (243 6 72 s vs. 259 6 64 s,
p 5 NS). In contrast, in group B sarpogrelate increased the
total exercise time from 181 6 112 to 248 6 131 s (p , 0.05)
(Fig. 1). There were no significant differences in resting
hemodynamic parameters between groups A and B. Sarpogre-
late did not change resting hemodynamic parameters in either
group. In group A, the baseline double product at 0.1 mV ST
depression was 23300 6 2800 mmHg beats/min which was
significantly (p , 0.05) higher than 16800 6 4800 mmHg
beats/min in group B. Sarpogrelate did not increase the double
product of ischemia in group A. However, in group B it was
significantly (p , 0.01) increased to 20300 6 4700 mmHg
beats/min with sarpogrelate pretreatment (Fig. 2).
Severity score with and without sarpogrelate treatment. At
the baseline, the severity score of resting tetrofosmin myocar-
dial perfusion scintigraphy was comparable in both groups
(2.8 6 1.9 in group A vs. 4.7 6 3.9 in group B). The severity
score of the exercise scintigraphy was 5.1 6 3.5 in group A
which was smaller than 9.3 6 4.5 in group B. After treatment
with sarpogrelate, the resting severity score remained un-
changed in each group (3.0 6 2.2 in group A; 3.3 6 2.9 in
Table 1. Clinical and Angiographic Data
Group A Group B
Patients (no.) 11 11
Age (yr) 64 6 11 68 6 10
Male 10 7
Female 1 4
Ischemia-related artery
RCA 2 2
LAD 6 6
LCx 3 3
Multivessel Disease 5 4
EF (%) 60 6 5 54 6 10
Data are presented as the number of patients or mean 6 SD. Group A 5
patients with TIMI grade 2 or 3 flow and Rentrop’s collateral index 0 or 1; group
B 5 patients with TIMI grade 0 or 1 flow and Rentrop’s collateral index 2 or 3.
EF 5 ejection fraction; LAD 5 left anterior descending coronary artery; LCx 5
left circumflex coronary artery; RCA 5 right coronary artery.
Table 2. Changes in Exercise Time and Hemodynamic Parameters at Rest and at 0.1 mV ST
Depression With and Without Sarpogrelate Treatment
Group A Group B
Baseline Sarpogrelate Baseline Sarpogrelate
Exercise Time (sec) 243 6 72 259 6 64 181 6 112† 248 6 131*
Heart Rate (beats/min)
resting 69 6 5 69 6 5 69 6 8 69 6 8
ischemia 112 6 8 114 6 9 108 6 17 116 6 18*
Systolic Blood Pressure (mmHg)
resting 144 6 16 143 6 18 139 6 22 137 6 22
ischemia 209 6 26 192 6 20 155 6 31† 177 6 43
Double Product 3 1022 (mmHg 3 beats/min)
resting 100 6 16 98 6 8 96 6 20 94 6 12
ischemia 233 6 28 218 6 17 168 6 48† 203 6 47**
*p , 0.05, **p , 0.01 vs. baseline values; †p , 0.05 vs. Group A. Data are presented as mean value 6 SD. Group
A 5 patients with severely stenosed ischemia-related coronary artery; Group B 5 patients with well-developed collateral
circulation.
Figure 1. Individual changes in the exercise time up to until 0.1 mV ST
depression after sarpogrelate pretreatment in groups A (patients with
severely stenosed ischemia-related coronary artery) and B (patients
with well-developed collateral circulation).
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group B). Although the severity score of the exercise scintig-
raphy was not different from the baseline study in group A
(5.1 6 3.5 to 3.0 6 2.2), it significantly (p , 0.01) decreased
from 9.3 6 4.5 to 5.8 6 3.6 in group B (Fig. 3).
Discussion
The present study clearly demonstrates that sarpogrelate
attenuates exercise-induced myocardial ischemia as a result of
enhancement of preexisting collateral circulation in patients
with stable effort angina. This is the first report, to the best of
our knowledge, which documents a drug in the antiplatelet
drug category which is effective in alleviating exercise-induced
myocardial ischemia in patients with coronary artery disease.
Collateral vascular reactivity. Well-developed collateral
vessels have several layers of muscular media and are capable
of vasomotion. These findings indicate that modulation of
collateral vessel tone can influence blood flow to the collateral
dependent myocardial area. Indeed, we have previously shown
that collateral vasodilation with nitrate administration contrib-
utes greatly to the improvement in exercise capacity of patients
with well-developed collaterals (1). In contrast, vasoactive
drugs that cause arteriolar vasodilation can be detrimental
because these agents can generate coronary steal. Adenosine is
one such agent which deteriorates myocardial ischemia by
reducing collateral blood flow as a result of coronary steal (8).
Data reported here strongly suggest that sarpogrelate is a
potent vasodilator of not only arteriolar resistance vessels but
also coronary collateral vessels.
Increase in collateral blood flow by sarpogrelate. In our
patients with well-developed collateral vessels, the rate-
pressure product at 0.1 mV ST depression increased by 21%
with sarpogrelate pretreatment. This implies an increase in
blood flow supply to the potentially ischemic collateral depen-
dent area (1,9,10). Furthermore, the augmentation of collat-
eral flow by sarpogrelate was confirmed by the stress myocar-
dial perfusion scintigraphy at the same workload. These
findings suggest that platelet activation, and the resultant
serotonin production and release in a coronary artery proximal
to the origin of collateral vessels, has the potential to decrease
blood flow to the dependent myocardium by causing collateral
vasoconstriction (2). Furthermore, a serotonin blocker, sar-
pogrelate, attenuated the effects of serotonin on coronary
collateral vessels.
Unchanged coronary flow through a stenosis with sarpogre-
late. In patients with severe coronary stenosis, but without a
significant collateral circulation, sarpogrelate did not increase
the rate-pressure product at 0.1 mV ST depression, nor did it
reduce the perfusion defect in the stress myocardial scintigra-
phy. These findings suggest that it is unlikely that platelet
aggregation and serotonin production and release at the site of
a coronary stenosis have the potential to produce coronary
vasoconstriction, either at the site of a stenosis, or in the distal
parts of the ischemia-related coronary artery. A report by
Ganz and Marcus (11) supports the above mentioned
speculation. In their study, intracoronary nitroglycerin had
no effect in reducing pacing-induced ischemia, probably
because of the absence of intact vascular smooth muscle
cells responsible for dealing with nitroglycerin at the site of
stenosis.
Limitations. First, to minimize the effects of habituation to
the treadmill exercise, it was repeated several times before the
study. However, the variation in exercise tolerance may exist
between the exercise tests with and without sarpogrelate
pretreatment. Nevertheless, Waters et al. (12) demonstrated in
patients with effort angina that the rate-pressure product at the
onset of ischemia remains relatively constant at repeated
treadmill exercise tests, despite considerable variations in the
exercise time up to the onset of ischemia. Second, although it
has previously been demonstrated that serotonin is released
into the coronary circulation of selected patients with coronary
artery disease (13), we did not measure aortic and coronary
sinus serotonin concentration in our patients. Further studies
are necessary to define the role of serotonin in patients with
effort angina. Finally, it is possible that sarpogrelate has
some other independent vasoactive properties which block
some other potential vasoconstrictor pathways. Sarpogrelate
is reported to be a specific 5HT2-receptor antagonist; a
compound having weak displacement potencies for other
receptors such as a1-, a2-, b-adrenoceptors, 5HT1-, or
muscarinic receptors (14). Thus, the beneficial effect of
Figure 2. Individual changes in the double product at 0.1 mV ST
depression after sarpogrelate pretreatment in groups A (patients with
severely stenosed ischemia-related coronary artery) and B (patients
with well-developed collateral circulation).
Figure 3. Individual changes in the severity score of the exercise
myocardial perfusion scintigrams after sarpogrelate pretreatment in
groups A (patients with severely stenosed ischemia-related coronary
artery) and B (patients with well-developed collateral circulation).
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sarpogrelate mainly depends on its action as a specific
serotonin antagonist.
Conclusions. We demonstrated that sarpogrelate increases
exercise capacity as a result of enhancement of collateral
circulation in anginal patients with well-developed collateral
channels. These findings indicate that sarpogrelate is useful
not only for suppressing platelet function, but also alleviating
exercise-induced myocardial ischemia in patients with effort
angina and well-developed collateral circulation.
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